Seragon Pharmaceuticals Obtains $30,000,000 Series A Financing

  • Feed Type
  • Date
    10/18/2013
  • Company Name
    Seragon Pharmaceuticals
  • Mailing Address
    12780 El Camino Real San Diego, CA 92130
  • Company Description
    Seragon Pharmaceuticals is developing small-molecule drugs for the treatment of estrogen receptor dependent breast cancer.
  • Website
    http://www.seragonpharm.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    This financing provides Seragon with the resources to advance our pipeline, including ARN-810 which is currently being evaluated in a Phase I trial for ER+ metastatic breast cancer.
  • M&A Terms
  • Venture Investor
    venBio
  • Venture Investor
    Topspin Partners
  • Venture Investor
    Aisling Capital
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    The Column Group

By posting a comment, you agree to our terms and conditions.